Redbiotec picks GE's single-use systems for Herpesvirus vaccine production

By Dan Stanton contact

- Last updated on GMT

Redbiotec is developing a vaccine for Cytomegalovirus
Redbiotec is developing a vaccine for Cytomegalovirus

Related tags: Immune system, Vaccine

Redbiotec has selected GE Healthcare’s single-use processing offering to aid development of its Herpesvirus vaccines which use viral antigen complexes and virus-like particles. 

Cytomegalovirus is a member of the Herpesvirus family, and there have been many attempts to apply traditional approaches such as attenuated viruses or single viral antigens to develop a vaccine, yet these efforts have failed to show sufficient efficacy in the clinics.

However, Redbiotec, a Zurich, Switzerland-based biotech firm developing vaccines against Cytomegalovirus using its proprietary rePAX assembly and expression platform, is challenging these approaches by using conformational viral antigen complexes as well as virus-like particles (VLPs).

“VLPs are true virus ‘mimics’ – they are recombinantly built out of the same proteins as the real pathogen and contain only the immunologically relevant antigens,” ​Redbiotec's Andreas Jurgeit told Biopharma-Reporter.com.  

“When presented to the body’s immune system, they are recognized like the real pathogen but they are not infectious. Redbiotec could for the first time show that it is possible to resemble CMV as a VLP and that VLPs can be optimized and produced to assure an optimal immune response.”

To progress its programmes and scale its production from prototype to GMP-compatible large scale bioreactors, the company has chosen single-use technology, and more specifically partnered GE Healthcare for its single-use Wave bioreactor and ReadyToProcess filtration system.

“GE’s solution is not just well integrated but remains flexible enough to adopt it to a variety of different products,”​ Jurgeit said.

“Besides in-house applications, Redbiotec could show that the processes developed can be readily transferred to external partners using the same platform. This is especially useful to on-demand scale production capacities in short time frames with limited investments.”

Related news

Show more

Related products

show more

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Single-Step Influenza and Dengue Virus Purification

Single-Step Influenza and Dengue Virus Purification

Bio-Rad Laboratories | 08-Oct-2018 | Application Note

CHT XT is the newest addition to the CHT family of media. It has been designed for superior physical robustness to ensure it can be used repeatedly over...

Downstream Purification of Large Biomolecules

Downstream Purification of Large Biomolecules

Bio-Rad Laboratories | 17-Sep-2018 | Research Study

Our newest strong anion exchange resin provides both high binding capacity and
high recovery, even at high flow rates. A rigid bead complete with...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Related suppliers

Follow us

Products

View more

Webinars